Daily Cardiology Research Analysis
Analyzed 171 papers and selected 3 impactful papers.
Summary
Analyzed 171 papers and selected 3 impactful articles.
Selected Articles
1. LDLR-OPN Interaction Drives COVID-19 Myocarditis Through Monocyte Recruitment.
A chimeric SARS-CoV-2 mouse model with cardiac LDLR overexpression produced fully penetrant, macrophage-rich myocarditis with pyroptosis, revealing a high-affinity LDLR–osteopontin interaction that recruits monocytes. Pharmacologic LDLR degradation abrogated disease and dimethyl fumarate reduced pyroptosis; human autopsy hearts showed marked LDLR upregulation, positioning the LDLR–OPN axis as a targetable driver of COVID-19 myocarditis.
Impact: Identifies a novel, targetable LDLR–osteopontin axis mechanistically driving COVID-19 myocarditis and demonstrates disease mitigation with pharmacologic perturbations, bridging rigorous preclinical modeling to human pathology.
Clinical Implications: Suggests therapeutic strategies targeting LDLR–OPN signaling or downstream pyroptosis (e.g., repurposing dimethyl fumarate) for viral myocarditis, warranting early-phase clinical trials with biomarker-guided patient selection.
Key Findings
- A reproducible mouse model achieved 100% penetrance of macrophage-predominant myocarditis with cardiomyocyte necrosis and gasdermin D–mediated pyroptosis.
- A previously unrecognized high-affinity interaction between LDLR (CR2–CR5) and osteopontin drives monocyte recruitment to the heart.
- Pharmacologic LDLR degradation abrogated myocarditis, and dimethyl fumarate reduced pyroptosis and inflammatory burden.
- Human myocarditis autopsy hearts exhibited >10-fold upregulation of LDLR and ICAM-1, recapitulating murine findings.
Methodological Strengths
- Integrated in vivo disease model with mechanistic mapping and human autopsy validation.
- Pharmacologic perturbation demonstrating causality (LDLR degrader; dimethyl fumarate).
Limitations
- Preclinical chimeric infection and overexpression model may not capture full human disease heterogeneity.
- Durability, safety, and clinical efficacy of targeting LDLR–OPN or pyroptosis remain untested in patients.
Future Directions: Biomarker-enriched early-phase trials of LDLR–OPN pathway inhibitors or pyroptosis modulators; delineation of patient subgroups with LDLR/OPN upregulation; comparative studies across viral myocarditis etiologies.
COVID-19-associated myocarditis is marked by macrophage-rich inflammation and adverse cardiac outcomes, yet its mechanisms remain unclear. We developed a reproducible BSL-2 mouse model by combining cardiac-specific human low-density lipoprotein receptor (LDLR) overexpression (AAV9-cTnT-hLDLR) with chimeric SARS-CoV-2 infection in keratin 18 human angiotensin-converting enzyme 2 transgenic mice, achieving 100% penetrance of macrophage-predominant myocarditis with cardiomyocyte necrosis and gasdermin D-mediated pyroptosis. We identified a previously unrecognized high-affinity interaction between LDLR (CR2-CR5 domains) and osteopontin that drives monocyte recruitment. Induced degrader of LDLR-mediated LDLR degradation completely abrogated myocarditis, while dimethyl fumarate significantly reduced pyroptosis and inflammatory burden. Importantly, human myocarditis autopsy hearts exhibited >10-fold up-regulation of LDLR and intercellular adhesion molecule-1, mirroring the murine findings. These data establish the LDLR-osteopontin axis as a mechanistic and targetable driver of COVID-19 myocarditis and provide a translational platform for therapeutic development in viral myocarditis.
2. Impact of artificial intelligence on cardiovascular workflow, engagement, and outcomes: a systematic review.
This randomized-trial systematic review found that AI interventions reduced workflow time (SMD −0.71), improved medication adherence (RR 1.59), and decreased all-cause mortality (RR 0.84) when embedded as decision support. Methodological limitations included limited blinding and few sham-AI controls.
Impact: Provides multi-tier, RCT-based evidence that AI can improve hard outcomes, not just efficiency, supporting responsible clinical deployment.
Clinical Implications: Health systems can prioritize AI tools with proven RCT benefits, integrate them with actionable decision support, and design governance including monitoring for bias. Future trials should include sham-AI controls and standardized outcome frameworks.
Key Findings
- Workflow time decreased with AI interventions (SMD −0.71; 95% CI −1.04 to −0.39).
- Patient engagement improved: behavioral nudging increased medication adherence (RR 1.59; 95% CI 1.01–2.50; NNT ≈ 12).
- Clinical outcomes improved: AI decision support reduced all-cause mortality (RR 0.84; 95% CI 0.75–0.94; I² = 8%; NNT ≈ 32).
Methodological Strengths
- Randomized controlled trials synthesized with meta-analysis and RoB 2.0 bias assessment
- Tiered outcome framework (NICE) spanning workflow, engagement, and clinical endpoints
Limitations
- Limited blinding and scarcity of sham-AI comparators
- Heterogeneity in AI interventions and settings; outcome standardization remains incomplete
Future Directions: Conduct adequately powered, sham-controlled RCTs with standardized endpoints, equity/bias audits, and health-economic evaluations to guide scalable implementation.
Artificial intelligence (AI) is progressively utilized in cardiology; nonetheless, the overarching advantages across various care domains remain ambiguous. We conducted a search of PubMed, Embase, CINAHL, and trial registries for randomized controlled trials up to January 16, 2026, assessing prospectively applied interventions based on machine/deep-learning algorithms while excluding rule-based systems. Endpoints were categorized according to NICE evidence tiers: workflow efficiency (Tier A), patient engagem
3. Interleukin-1β Drives Disease Progression in Arrhythmogenic Cardiomyopathy.
snRNA-seq and spatial transcriptomics of human ACM hearts revealed inflammatory–fibrotic niches with FAP/POSTN+ fibroblasts and NLRP3-expressing macrophages colocalized to myocyte loss, implicating IL-1β pathway activity. A Dsg2 mutant model supported these findings, positioning IL-1β signaling as a driver of ACM progression and a potential therapeutic target.
Impact: Connects cell-resolved human pathology to a mechanistic cytokine axis in ACM, offering a rationale for targeted anti–IL-1 therapies in a disease with limited options.
Clinical Implications: Supports exploration of IL-1 pathway inhibition (e.g., anakinra/canakinumab class) in ACM, with biomarker-guided selection and imaging endpoints to monitor inflammatory–fibrotic niches.
Key Findings
- Human ACM myocardium harbors inflammatory–fibrotic spatial niches with FAP/POSTN+ fibroblasts and NLRP3-expressing macrophages.
- These niches colocalize to areas of cardiomyocyte loss and NF-κB activation, implicating IL-1β signaling.
- A Dsg2 mutant model recapitulates key inflammatory–fibrotic features, supporting causative involvement of IL-1β–NLRP3 axis.
Methodological Strengths
- Multi-omic, cell-resolved profiling (snRNA-seq and spatial transcriptomics) directly in human myocardium.
- Cross-validation in a genetic mouse model strengthens mechanistic inference.
Limitations
- Abstract lacks quantitative sample sizes and interventional validation details (e.g., direct IL-1β blockade effects).
- Translational generalizability to diverse genotypes and disease stages remains to be established.
Future Directions: Prospective biomarker-defined trials of IL-1 blockade in ACM; longitudinal imaging–omics to track inflammatory–fibrotic niches and relate to arrhythmic outcomes.
Arrhythmogenic cardiomyopathy (ACM) is a genetic form of heart failure that affects 1 in 5,000 people globally and is caused by mutations in cardiac desmosomal genes including PKP2, DSP, and DSG2. Individuals with ACM suffer from ventricular arrhythmias, sudden cardiac death, and heart failure. There are few effective treatments and heart transplantation remains the best option for many affected individuals. Here we performed single nucleus RNA sequencing and spatial transcriptomics on myocardial samples from patients with ACM and control donors. We identified disease-associated spatial niches characterized by coexistence of fibrotic and inflammatory cell types and failing cardiac myocytes. The inflammatory-fibrotic niche colocalized to areas of cardiac myocyte loss and comprised FAP (fibroblast activation protein) and POSTN (periostin) expressing fibroblasts, macrophages that expressed NLRP3, and nuclear factor κB activated genes. Using homozygous Dsg2 mutant (Dsg2